IBMS-iPSC-012-12

General#

Cell Line

hPSCreg Name IBMSi001-A
Alternative name(s)
IBMS-iPSC-012-12
Cell line type Human induced pluripotent stem cell (hiPSC)
Last update 22nd May 2019
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Institute of Biomedical Sciences, Academia Sinica (IBMS)
Derivation country Taiwan

External Databases

BioSamples SAMEA104387150
Cellosaurus CVCL_LJ95

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research: allowed
Clinical: not allowed
Commercial: not allowed

Donor Information#

General Donor Information

Sex male
Age of donor (at collection) 35-39
Ethnicity East Asian (Taiwanese)

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
Autosomal dominant polycystic kidney disease
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • Polycystic kidneys - adult type
  • Autosomal dominant adult polycystic kidney disease
  • ADPKD
  • adult type autosomal dominant polycystic kidney disease
  • Polycystic kidney disease, adult type (disorder)
  • Autosomal dominant polycystic kidney disease
  • polycystic kidney disease, adult type
  • ADPKD - Autosomal dominant polycystic kidney disease
  • polycystic kidney, autosomal dominant
  • polycystic kidney disease, autosomal dominant
  • autosomal dominant polycystic kidney disease
show more synonyms
Genetic variants
Chr16:2160801_2delTC (p.Ser1457fs)
Heterozygous

Karyotyping (Donor)

Has the donor karyotype been analysed?
Yes
Karyotyping method: G-Banding

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
Yes

External Databases (Donor)

BioSamples SAMEA104388070

Ethics#

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? No
Provide contact information of the holder of the original Donor Information Sheet: michellelee@ibms.sinica.edu.tw
Do you (Depositor/Provider) hold a copy of the SIGNED Donor Consent Form? No
If you do not hold the SIGNED Donor Consent Form, do you know who does? Yes
Contact information / weblink michellelee@ibms.sinica.edu.tw
If you do not hold the SIGNED Donor Consent Form, have you obtained a copy of the unsigned Donor Consent Form from the holder? No
Alternatives to consent
Alternative consent approval number
Has the donor agreed to be re-contacted? Unknown
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. anonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Details on restriction to research project
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? Yes
Policy for access to genetic information No information
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Please describe how access is provided:
Contact data, institution, or website:
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? Institution Review Board on biomedical science research at Academia Sinica Taiwan and Kaohsiung Medical University Hospital
Approval number (AS-IRB-BM-15019) (KMUHIRB-20140116)
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? No
Name of accrediting authority involved?
Approval number
Please describe:
Further constraints on use
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?
Constraints for use or distribution

hIPSC Derivation#

General

Source cell type
peripheral blood mononuclear cell
A leukocyte with a single non-segmented nucleus in the mature form found in the circulatory pool of blood.
Age of donor (at collection) 35-39

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Is reprogramming vector detectable?
No
Methods used
PCR

Vector free reprogramming

Other

Derived under xeno-free conditions
Unknown
Derived under GMP?
Unknown
Available as clinical grade?
Unknown

Culture Conditions#

Medium Other medium:
Base medium: DMEM/F12
Main protein source: Knock-out serum replacement
Serum concentration: 20 %
Supplements
NEAA 0.1 mM
Glutamine 1 mM
2-mercaptoethanol 0.1 mM
bFGF 10 ng/ml
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles
Differentiation Potency
Glandular structure
In vivo teratoma
Cartilage Element
Ont Id: UBERON_0007844
In vivo teratoma
Neural tissue
In vivo teratoma

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46 XY
Karyotyping method: G-Banding

Other Genotyping (Cell Line)